Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Leukemia and Nuclear Transport Inhibition.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NUP214 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NUP214 Recombinant Protein (FG-Repeat Domain) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View NUP214 Products |
| Gene Delivery | NUP214 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and localization assays. |
View NUP214 Products |
| Benchmark Ab | Anti-NUP214 Recombinant Antibody Recombinant positive control for Western Blot and Immunofluorescence. |
View NUP214 Products |
| Validator | NUP214 siRNA Set For knockdown verification and functional specificity assays. |
View NUP214 Products |
| Related Target A | XPO1 (CRM1) Nuclear export receptor that physically interacts with NUP214 FG-repeats; key target for Selinexor. |
View XPO1 Products |
| Related Target B | DEK Fusion partner forming the oncogenic DEK-NUP214 translocation in acute myeloid leukemia (AML). |
View DEK Products |
| Related Target C | SET Fusion partner forming the oncogenic SET-NUP214 translocation in T-cell acute lymphoblastic leukemia (T-ALL). |
View SET Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting CRM1-NUP214 interaction | High-purity, sequence-verified FG-repeat domain proteins and XPO1 partner proteins available. |
| High-molecular-weight target expression | Domain-specific truncated recombinants optimized for high yield and theoretical MW verification. |
| Lack of Controls | Sequence-derived recombinant positive control antibodies included. |
| False Positives | Validated siRNA sets included for target specificity verification. |
Live NUP214 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NUP214-associated therapeutics is intensifying, with major players shifting focus from traditional chemotherapy to targeted nuclear export inhibition and fusion-protein degradation. As first-generation XPO1 (CRM1) inhibitors reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions of the DEK-NUP214 and SET-NUP214 oncogenic fusion products.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (XPO1/CRM1 Inhibitors) | Karyopharm Therapeutics, Antengene | Multiple Myeloma, DLBCL, AML | Protein-Protein Interaction (PPI) blocking assay (Need high-purity XPO1 and NUP214) |
| Targeted Protein Degraders (PROTACs) | Academic Institutions, Biotech Startups | DEK-NUP214+ AML, SET-NUP214+ T-ALL | Fusion protein expression validation (Need Lentivirus for stable cell lines) |
| siRNA / Oligonucleotides | Preclinical Discovery Stage | Refractory Leukemias | Knockdown efficiency verification (Need sequence-specific siRNA sets) |